AstraZeneca, Britain’s largest listed drugmaker with a market value of approximately £196bn, is in discussions to acquire Bristol Myers Squibb in a transaction that would value the combined entity at nearly $400bn. The Princeton-based BMS, known for its cancer treatments and valued at $133bn, would become part of a merged entity under AstraZeneca’s leadership.
The potential transaction would rank among the largest-ever pharmaceutical mergers and establish a fourth-largest drugmaker globally by market value. AstraZeneca’s stock declined more than 7% on the announcement, while BMS shares rose 3.5% in pre-market trading. The tie-up would expand AstraZeneca’s footprint in the United States, where the company is already investing $50bn in research and manufacturing through 2030. AstraZeneca completed a direct listing on the New York Stock Exchange earlier this summer.
Market observers expressed skepticism regarding the deal’s strategic rationale. Analysts highlighted substantial regulatory obstacles, particularly given the overlap between the two companies’ oncology portfolios. Some questioned whether a merger would distract from pipeline development, noting that rival firms have successfully pursued alternative strategies for acquiring pipeline assets, particularly in China. BMS has faced challenges since 2023, raising questions among some shareholders about the timing and expense of the proposed acquisition.
No assurance exists that discussions will culminate in a completed transaction, according to sources. AstraZeneca, headquartered in Cambridge and formed in 1999, has experienced significant share price appreciation under Chief Executive Pascal Soriot. The company previously rebuffed a hostile takeover bid from Pfizer valued at nearly £70bn and has since rebuilt its pipeline with cancer immunotherapies and other treatments. BMS recently beat Wall Street expectations with second-quarter results and raised its 2026 outlook.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI